SEC Comment Letter 0000000000-23-002624 to BriaCell Therapeutics Corp. (BCTX)

BriaCell Therapeutics Corp.
Date: March 16, 2023 · CIK: 0001610820 · Accession: 0000000000-23-002624

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-40101

Date

March 16, 2023

Author

Gadi Levin

Form

UPLOAD

Company

BriaCell Therapeutics Corp.

Letter

United States securities and exchange commission logo March 16, 2023 Gadi Levin Chief Financial Officer BriaCell Therapeutics Corp. Suite 300 - 235 15th Street West Vancouver, BC V7T2X1 Re:BriaCell Therapeutics Corp. Form 10-K for the Fiscal Year Ended July 31, 2022 Filed October 28, 2022 File No. 001-40101 Dear Gadi Levin: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
March 16, 2023
Gadi Levin
Chief Financial Officer
BriaCell Therapeutics Corp.
Suite 300 - 235 15th Street
West Vancouver, BC V7T2X1
Re:BriaCell Therapeutics Corp.
Form 10-K for the Fiscal Year Ended July 31, 2022
Filed October 28, 2022
File No. 001-40101
Dear Gadi Levin:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io